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A marginal ulcer is deﬁned as an ulcer at or around a gastrointestinal anastomosis following 
partial gastric resection,  pancreaticoduodenectomy 
(PD),  pylorus-preserving pancreaticoduodenectomy 
(PPPD) or Roux-en-Y gastric bypass (RYGB).  The 
incidence of marginal ulcer following these procedures 
has been reported as 1-16  [1-5].  A marginal ulcer 
typically presents on the jejunal side of the anastomo-
sis,  due to several factors such as gastric acid and 
local ischemia.  Upper gastrointestinal bleeding is a 
major clinical complication of marginal ulcers,  and this 
bleeding is considered to be more severe than that of 
a peptic ulcer bleeding from a non-operative stomach 
[6,7].
　 Although there have been great advances in endo-
scopic therapy and medication,  marginal ulcer bleed-
ing is still a common medical condition that results in 
a high rate of morbidity [8,9].  The eﬃcacy of thera-
peutic endoscopy in active marginal ulcer bleeding has 
rarely been studied [9,10].  In addition,  although 
proton pump inhibitors (PPIs) are eﬀective in treating 
gastroduodenal ulcers [11-13],  the role of PPIs in 
the prevention of rebleeding from marginal ulcers is 
unclear.  The aim of this study was to assess the safety 
and eﬃcacy of therapeutic endoscopy in the treatment 
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The usefulness of endoscopy in marginal ulcer bleeding has rarely been studied,  and the optimal 
method for preventing rebleeding is unclear.  Here we assessed the eﬃcacy of endoscopy in marginal 
ulcer bleeding and examined the eﬃcacy of proton pump inhibitors (PPIs) in the prevention of rebleed-
ing.  A total of 28 patients with marginal ulcer bleeding (21 men,  7 women; median age 58.5 years) 
were treated by endoscopy.  We analyzed the clinical characteristics,  results of endoscopic therapy,  
characteristics of rebleeding patients,  and relation between the use of PPIs and the duration of 
rebleeding.  Sixteen patients had active bleeding.  Initial hemostasis was achieved in all patients.  There 
were no procedure-related adverse events.  Rebleeding occurred in one patient within the ﬁrst month 
and in 7 patients thereafter.  There was a signiﬁcant diﬀerence in the rebleeding rate between the 
patients who received a PPI and those who did not.  In a multivariate analysis,  the non-use of PPIs was 
a risk factor for rebleeding (hazard ratio,  6.22).  Therapeutic endoscopy is eﬀective in achieving hemo-
stasis from marginal ulcer bleeding.  PPIs may prevent rebleeding from marginal ulcers.
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of patients with active or recent marginal ulcer bleed-
ing.  We also examined the eﬃcacy of PPIs in the 
prevention of rebleeding from marginal ulcers.
Materials and Methods
　 Patients and methods. Between January 2000 
and July 2012,  a total of 87 patients with marginal 
ulcers underwent upper gastrointestinal endoscopy at 
Okayama University Hospital and Tsuyama Chuo 
Hospital.  Among those,  54 patients were excluded 
from this study because they had non-bleeding mar-
ginal ulcers.  Of the remaining 33 patients,  5 were 
excluded because they were treated by conservative 
therapy.  A total of 28 patients with active or recent 
marginal ulcer bleeding treated by endoscopic therapy 
were thus enrolled in this study (Fig. 1).
　 Emergency upper gastrointestinal endoscopy was 
performed within 24 h after a patient ﬁrst visited 
either of the above-named hospitals if hematemesis,  
melena or progressive anemia were seen.  When emer-
gency endoscopy was performed,  a standard for-
ward-viewing endoscope was used.  Endoscopic therapy 
was performed when a marginal ulcer with bleeding 
stigmata was disclosed.  The bleeding stigmata were 
classiﬁed into Forrest Ia (spurting bleed),  Forrest Ib 
(oozing bleed),  Forrest IIa (non-bleeding visible ves-
sel),  or Forrest IIb (adherent blood clot).
　 Endoscopic therapy such as hemoclips,  heater 
probe coagulation,  soft coagulation,  and/or hyper-
tonic saline with epinephrine (HSE) was selected 
depending on the situation.  Hemoclips (HX-610-135,  
HX-610-135XS,  HX-610-090L,  Olympus,  Tokyo,  
Japan) were deployed to the bleeding point,  and then 
the vessel was clamped.  The heater probe (HPU-20,  
Olympus) was used at pulses of 20-30 J.  The distal 
tip of the heater probe was applied directly to the 
bleeding site.  Soft coagulation was performed using 
monopolar,  hemostatic forceps (FD-410LR,  Olympus,  
or HDB2418W,  Pentax,  Tokyo,  Japan) and an elec-
trosurgical unit (ICC-200,  ERBE,  Tübingen,  Germany) 
at soft-mode coagulation with a 70W current.  The 
hemostatic forceps was applied directly over the bleed-
ing vessels or visible vessels [14-16].
　 HSE injection therapy was performed mainly as 
combination therapy when it was diﬃcult to maintain a 
good view because of blood spurting or oozing during 
the procedure.  HSE was injected into the ulcer bed or 
around the ulcer.  When the bleeding was stopped and 
the vessel had disappeared after the HSE injection,  
hemostasis was considered to be attained by HSE 
monotherapy.  When the bleeding could not be stopped 
by endoscopic therapy,  intervention radiology (IVR) 
or surgical therapy was performed.  The endoscopic 
therapy was performed by endoscopists who had at 
least 2 years of upper gastrointestinal endoscopy 
experience.  Before emergency endoscopy,  written 
informed consent was obtained from all patients or 
their relatives.
　 H. pylori infection was checked by using a serum IgG 
antibody to H. pylori or by the rapid urease test.  The 
operation etiology and method of reconstruction were 
checked using operative notes or medication records.
　 Initial hemostasis was deﬁned as the endoscopically 
veriﬁed cessation of bleeding and the disappearance of 
visible vessels when the ﬁrst endoscopic therapy was 
ﬁnished.  A second-look endoscopy was routinely per-
formed to conﬁrm hemostasis within 24 h of prior 
endoscopic therapy.  Patients with marginal ulcer 
bleeding were managed with intravenous lansoprazole 
30 mg,  omeprazole 20 mg or famotidine 20 mg every 
12 h for 2 days after initial hemostasis.  A oral PPI 
(i.e.,  lansoprazole 30 mg/day,  omeprazole 20 mg/day,  
or rabeprazole 10 mg) was then administered for 2 
months.  The PPI was continued in the patients with 
gastroesophageal reﬂux disease thereafter.  Some 
patients who received anti-platelet drugs including 
low-dose aspirin and non-steroidal anti-inﬂammatory 
drugs were also managed with oral PPI.
　 Rebleeding was suspected when the patient pre-
sented with tarry stools and/or fresh hematemesis and 
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Fig. 1　 Patient ﬂow chart.
was conﬁrmed when emergency endoscopy revealed 
active or recent rebleeding from the marginal ulcers.  
When rebleeding occurred,  it was treated again with 
endoscopic therapy.  Surgery or IVR was performed 
if the endoscopic therapy still did not stop the 
rebleeding.  Ultimate hemostasis was deﬁned as the 
successful control of bleeding including rebleeding 
after the endoscopic therapy until the end of the fol-
low-up.
　 We stratiﬁed the patients in whom ultimate hemo-
stasis was attained by endoscopic treatment into 2 
groups according to whether they had received a PPI 
or not,  based on their medical records or telephone 
interviews.  The clinical characteristics of each group 
and the eﬃcacy of the PPIs were retrospectively ana-
lyzed.  This study was approved by the Ethics 
Committee of our hospitals (No. 782).
　 Statistics. The signiﬁcance of diﬀerences 
between each group of patients was determined by the 
chi-square test or Fisherʼs exact test for discontinu-
ous variables and the Mann-Whitney U-test for contin-
uous variables.  We used the Kaplan-Meier method to 
analyze the rebleeding curve,  and the diﬀerences 
between each group were estimated using the log-rank 
test.  For estimating the risk factors associated with 
time to rebleeding,  we used the Cox proportional haz-
ards regression model.  JMP software ver.  8 (SAS,  
Cary,  NC,  USA) was used for all statistical analyses.  
P-values＜0.05 were considered signiﬁcant.
Results
　 Table 1 summarizes the clinical characteristics of 
the patients.  The subjects were 21 men and 7 women 
with a median age of 58.5 years.  Of the 28 patients,  
14 had undergone a partial gastric resection due to 
peptic ulcers.  The interval between the patientsʼ oper-
ations and the episode of bleeding ranged from 0 to 57 
years (median 10.0 years).  The location of each ulcer 
was classiﬁed as follows: anastomotic site,  20 (71 );  
saddle portion,  6 (21 ); eﬀerent loop,  2 (7 ); aﬀer-
ent loop,  0 (0 ).  Sixteen patients had active bleeding 
(4 spurting and 12 oozing bleeds).
　 Table 2 shows the results of the endoscopic thera-
pies.  Initial hemostasis was achieved in 28 patients 
(100 ).  Rebleeding occurred in one patient with an 
anastomotic site marginal ulcer 5 days after the initial 
hemostasis.  The patient received heater probe coagu-
lation following HSE at the ﬁrst treatment,  and was 
administered lansoprazol for 5 days.  Emergency endos-
copy revealed that the size of the exposed vessel was 
5 mm in dia.  Because contrast-enhanced computed 
tomography showed that the vessel was a pseudo-aneu-
rysm arising from the gastroduodenal artery,  this 
patient was treated with IVR,  resulting in permanent 
hemostasis.
　 More than 1 month after the treatment,  rebleeding 
occurred in 7 patients (25 ).  They were treated with 
endoscopic therapy again,  resulting in permanent 
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Table 1　 Characteristics of the 28 patients with marginal ulcer 
bleeding
n %
Age (yrs) ＊58.5 (26-88)
　　　　Male 21 75%
　　　　Female 7 25%
H. pylori infection
　　　　Positive 4 14%
　　　　Negative 10 36%
　　　　Unknown 14 50%
Drug use
　　　　Anti-platelet drugs 3 11%
　　　　Anticoagulants 0 0%
　　　　NSAIDs 7 25%
Operation etiology
　　　　Gastric ulcer 5 18%
　　　　Duodenal ulcer 9 32%
　　　　Gastric cancer 7 25%
　　　　Pancreatic cancer 5 18%
　　　　Traumatic pancreatic injury 1 4%
　　　　Unknown 1 4%
Method of reconstruction
　　　　B-I 14 50%
　　　　B-II/R-Y/etc. 14 50%
Interval between operation and 
the episode of bleeding (yrs)
＊10.0
(0-57)
Location of ulcer
　　　　Anastomotic site 20 71%
　　　　Saddle portion 6 21%
　　　　Eﬀerent loop 2 7%
Bleeding stigmata
　　　　Spurting bleed 4 14%
　　　　Oozing bleed 12 43%
　　　　Non-bleeding visible vessel 9 32%
　　　　Adherent blood clot 3 11%
＊Values are median (range).  NSAIDs,  nonsteroidal anti-inﬂamma-
tory drugs.
hemostasis.  Among them,  6 patients did not receive a 
PPI because rebleeding occurred＞4 months after the 
initial hemostasis.  There were no procedure-related 
adverse events.
　 Table 3 shows the characteristics of the patients 
stratiﬁed into 2 groups according to whether they 
received a PPI or not after marginal ulcer healing.  
There were no signiﬁcant diﬀerences between the 2 
groups regarding age,  sex,  drug use,  operation etiol-
ogy,  method of reconstruction,  or the location of the 
ulcer.  Rebleeding was more likely to develop in the 
non-PPI group,  but the diﬀerence was not signiﬁcant 
(p＝0.077).  When the observation period was consid-
ered,  a signiﬁcant diﬀerence was observed in the 
rebleeding rates between the 2 groups (p＝0.047) 
(Fig. 2).
　 In the multivariate analysis adjusted for age and 
sex,  non-PPI was a risk factor for rebleeding (inci-
dence of rebleeding,  hazard ratio [HR]＝6.22,  conﬁ-
dence interval [CI] 1.01-119.3).  Rebleeding occurred 
in only one patient in the PPI group.  This patient had 
undergone a gastric bypass for traumatic pancreatic 
injury.  The patientʼs initial bleeding occurred 2 years 
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Table 3　 Characteristics of the patients who did/did not receive a PPI after marginal ulcer healing
PPI Non-PPI p-value
n 13 14
Age 59 (36-88) 55.5 (26-78) 0.23
　　　　Male 10 11 0.92
　　　　Female 3 3
Drug use
　　　　Anti-platelet drugs 2 1 0.50
　　　　NSAIDs 4 3 0.58
Operation etiology
　　　　Gastric ulcer 3 2  0.23
　　　　Duodenal ulcer 2 7
　　　　Gastric cancer 3 3
　　　　Pancreatic cancer 4 1
　　　　Traumatic pancreatic injury 1 0
　　　　Unknown 0 1
Method of reconstruction
　　　　B-I 7 6 0.56
　　　　B-II/R-Y/etc. 6 8
Location of ulcer
　　　　Anastomotic site 11 8 0.21
　　　　Saddle portion 1 5
　　　　Eﬀerent loop 1 1
Outcome
　　　　Rebleeding 1 6 0.077
NSAID: non-steroidal anti-inﬂammatory drug.
Table 2　 Results of the endoscopic therapies
n %
Initial hemostasis 28 100%
　　Hemoclips  9 32%
　　Hemoclips following HSE  2 7%
　　Heater probe coagulation  6 21%
　　Heater probe coagulation following HSE  3 11%
　　Soft coagulation  3 11%
　　Soft coagulation followed by hemoclips  2 7%
　　HSE  3 11%
Rebleeding within the 1st month  1 4%
Rebleeding after the 1st month  7 25%
Ultimate hemostasis 27 96%
Perforation  0 0%
Emergency IVR or surgery  1 4%
HSE,  hypertonic saline with epinephrine; IVR,  interventional 
radiology.
after the operation,  and rebleeding occurred 9 months 
after the initial hemostasis.
Discussion
　 Marginal ulcer bleeding is one of the most severe 
complications after gastric resection,  PD,  or RYGB 
[9,10,17,18].  Few reports have been published on 
endoscopic hemostasis for marginal ulcer bleeding or 
long-term outcomes after the treatment,  because the 
incidence of marginal ulcer bleeding is relatively low 
[9,10].  In the present study,  endoscopic hemostasis 
was achieved in all 28 patients,  and rebleeding 
occurred in one patient (4 ) within the ﬁrst month.  
After the ﬁrst month,  rebleeding occurred in 7 
patients (25 ),  and the patient management that did 
not include a PPI was a signiﬁcant risk factor associ-
ated with rebleeding.
　 Although marginal ulcer bleeding after gastrec-
tomy was reported to be more severe than peptic ulcer 
bleeding in a non-operated stomach [6,7],  several 
reports suggested that endoscopic therapy was safe 
and eﬀective in controlling marginal ulcer bleeding 
[6,7,9,10].  In those reports,  initial hemostasis for 
marginal ulcer bleeding was achieved in 88-100  of 
the procedures,  but the rebleeding rate within the ﬁrst 
month was high (5-33 ) (Table 4).  In the present 
study,  initial hemostasis was achieved in all 28 
patients and the incidence of rebleeding within the ﬁrst 
month was only 4  (1/28).
　 We suspect that the reasons why it was possible to 
control marginal ulcer bleeding in our patients were as 
follows.  First,  we tried to ensure a good endoscopic 
view because marginal ulcer bleeding was often located 
at narrow and tight spaces.  HSE was applied to con-
trol bleeding,  and disposable soft straight transparent 
attachments were used to obtain the optimal distance.  
Second,  we selected an appropriate endoscopic method 
according to the situation.  When a correct frontal 
positioning against the bleeding point was easily 
obtained,  hemoclips or thermal coagulation was useful 
to achieve hemostasis.  When the ulcer was small and 
it was possible to close the border of the ulcer,  hemo-
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Table 4　 Outcomes of endoscopic treatments for marginal ulcer bleeding
First Author No. ofpatients
Age,
mean
M/F
ratio
Interval between
operation and the
bleeding (range)
Endoscopic
Treatment
Initial
hemostasis
rate (%)
Rebleeding
rate within the
1st mo. (%)
Rebleeding
rate after the
1st mo. (%)
Chung [6] 14 62 － － － － 16 －
Nikolopoulous [7] 35 68 － － Hemoclips,Epinephrine inj. － 12 －
Lee [9] 50 65 39/11 19 yrs(2-40 yrs)
Hemoclips,
Epinephrine inj.
and Heater probe
100 ¶5-33 －
Shin [10] 18 65 18/0 13 yrs(1-30 yrs)
Epinephrine inj.,
Alcohol inj.,
Heater probe
 88 － －
Our report 28 ||58 21/7 10 yrs(0-57 yrs)
Hemoclips,
Heater probe,
Soft coagulation
100  4 25
||Age is the median.  ¶The rebleeding rate after hemoclips was 5%.  The rebleeding rate after epinephrine injection and heater probe was 
33%.  M/F: male to female ratio.
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Fig. 2　 Kaplan-Meier curves for rebleeding rates in the patients 
who did/did not receive a PPI after marginal ulcer healing.  There 
was a signiﬁcant diﬀerences between the 2 groups (p＝0.047).
clips were particularly useful.  In the patients in whom 
frontal positioning was diﬃcult,  thermal coagulation 
such as soft coagulation with hemostatic forceps could 
achieve hemostasis even from a tangential direction.  
Compared with heater probe thermal coagulation,  soft 
coagulation with hemostatic forceps yielded a higher 
hemostasis success rate and lower rebleeding rate for 
peptic ulcer bleeding [16].
　 Long-term outcomes of marginal ulcer bleeding 
have rarely been studied.  Our present analysis showed 
that the rebleeding rate after the ﬁrst month was very 
high (25 ) in the marginal ulcers (Table 4).  In most 
cases,  the marginal ulcer recurred in the same loca-
tion after the patient stopped taking a PPI.  Only one 
patient was administered a PPI when rebleeding 
occurred; this patient had undergone bypass surgery 
due to a traumatic pancreatic injury.  The reason why 
rebleeding occurred in this patient despite the PPI 
treatment is unclear.
　 Among factors such as gastric acid,  H. pylori infec-
tion,  local ischemia,  anastomotic tension,  tobacco use,  
and NSAID use,  increased gastric acid is considered 
a main cause of marginal ulcers [6,19-21].  Because 
PPIs suppress gastric acid,  they might be useful to 
prevent marginal ulcer [22,23].  However,  it has not 
been determined whether PPIs are eﬀective in pre-
venting the recurrence and bleeding of marginal ulcers.  
In light of the results of the present study,  it is note-
worthy that PPIs might have the potential to prevent 
the recurrence of marginal ulcer bleeding regardless 
of the use of NSAIDs or anti-platelet drugs.
　 H. pylori plays an important role in the pathogenesis 
of marginal ulcers after gastric bypass,  and the erad-
ication of H. pylori reduced the incidence of postoper-
ative marginal ulcers [24-27].  However,  the associ-
ation between marginal ulcers after gastric resection 
or PD and H. pylori infection remains unclear [6,28].  
In the present study,  rebleeding occurred 8 months 
after the eradication of H. pylori in one patient who had 
undergone a partial gastric resection.  This patient was 
not administered a PPI at that time.  The patient had 
no co-morbidity and did not use NSAIDs.  After the 
rebleeding was treated,  a PPI was administered and 
re-rebleeding did not occur for another 2 years.  This 
result demonstrated that the eradication of H. pylori 
might not be enough to prevent marginal ulcer bleed-
ing,  although further studies to clarify the role of H. 
pylori are needed.
　 The limitations of our study are the small sample 
size and the retrospective design.  A randomized pro-
spective study may be necessary to clarify whether 
PPIs are useful for preventing rebleeding from mar-
ginal ulcers.
　 In conclusion,  therapeutic endoscopy is eﬀective 
and safe for achieving initial hemostasis and managing 
rebleeding in patients with active or recent marginal 
ulcer bleeding.  The administration of a PPI might 
prevent rebleeding from a marginal ulcer.
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